autoimmune disorders
-
Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds
Acelyrin has in-licensed izokibep, an antibody drug developed by Affibody that could offer advantages compared to currently available monoclonal antibodies. The drug addresses the same target as blockbuster immunology drugs marketed by Novartis and Eli Lilly.
-
FDA cracks down on JAK drug class, calls for new warnings of heart, cancer risks
The FDA’s review of a post-marketing study for Pfizer blockbuster anti-inflammatory drug Xeljanz found a higher risk of cardiovascular problems and cancer, and the agency is requiring additional warnings flagging those risks. The updated warnings extend to AbbVie and Eli Lilly medicines in the same drug class.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
First drug discovery startup emerges from GSK-Avalon deal to take on celiac disease
The $495 million innovation collaboration between GlaxoSmithKline and early-stage investor Avalon Ventures has produced its […]
-
Like a meteorologist for your health, Good Days forecasts flare ups in autoimmune conditions
For people with autoimmune disease, the temperature, humidity or barometric pressure on any given day […]
-
Combo of smoking while overweight boosts RA incidence
MADRID (IMNG) – Researchers have begun testing whether immunologic modification can forestall rheumatoid arthritis in […]
-
Stealthy biotech raises $5.3M for T-cell-specific immunosuppressants for autoimmune diseases
Another early stage California company in stealth mode has garnered a round of financing. This […]
-
Biopharma testing celiac disease drug to break down gluten
A biopharmaceutical company that’s already raised at least $42 million for its celiac disease drug […]
-
New anti-interferon alpha therapy for lupus nabs $5.8M, could start clinical trials next year
The approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug […]
-
Baxter Ventures, other investors pump $4.9M into cancer/immune disorder drug startup
Gliknik, which is testing cancer drugs and has developed a compound that it hopes will mimic the effects of IVIG, has just raised $4.9 million, some of it coming from Baxter Ventures.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.